<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089126</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GGCL001</org_study_id>
    <nct_id>NCT02089126</nct_id>
  </id_info>
  <brief_title>Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to demonstrate the superiority and safety of the combination therapy
      (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride
      monotherapy in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Changes</measure>
    <time_frame>Week 0, Week 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Gemigliptin/Glimepiride combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination &amp; Placebo for Glimepiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination &amp; Glimepiride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin/Glimepiride combination</intervention_name>
    <arm_group_label>Gemigliptin/Glimepiride combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type 2 diabetes

          2. Adults who are at least 19 years old

          3. Patients who have taken Glimepiride at a stable dose (≥4mg/day) for 8 weeks or more
             before Visit 1 (screening) as monotherapy or Patients who have taken Glimepiride at a
             stable dose (≥4mg/day) and Metformin for 8 weeks or more before Visit 1 (screening) as
             combination therapy

          4. Patients who satisfy the following HbA1c (%) criteria: 7 ≤ HbA1c ≤ 11

          5. Patients who have been provided an explanation about the objective, method, effects,
             etc. of the clinical trial and whose informed consent form has been signed by
             himself/herself or his/her representative

          6. Patients who fall under one of the following 3 cases

               1. Patients who are surgically sterile

               2. Post-menopausal females who are above 45 years of age and 2 years after the last
                  menstruation

               3. Fertile premenopausal female patients or male patients without having a surgical
                  sterilization, who have agreed to use at least two contraception methods (one of
                  the barrier methods must be included) for up to 14 days after the administration
                  of the last investigational product to avoid pregnancy.

        Exclusion Criteria:

          1. Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma

          2. Patients with gestational diabetes or secondary diabetes

          3. Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring
             treatment

          4. Patients with thyroid gland dysfunction and TSH that is out of normal range

          5. Patients with pituitary insufficiency or adrenal insufficiency

          6. Patients with hereditary problems, such as galactose intolerance, Lapp lactose
             deficiency or glucose-galactose malabsorption

          7. Female patients who are pregnant or breastfeeding

          8. Patients whose BMI exceeds 40 kg/m2

          9. Patients whose creatinine clearance is below 30mL/min/1.73m2

         10. Patients whose bilirubin level exceeds 1.5 times the upper limit of the normal range
             and whose ALT/AST level exceeds 2.5 times the upper limit of the normal range

         11. Patients who are continuously taking the following drugs for 2 weeks or more at Visit
             1 (screening), or need to take them continuously and repeatedly

               -  cyclosporin, sirolimus, tacrolimus, nicotinic acid (≥1500mg/day), isotretinoin

               -  Strong CYP3A4 inducers: rifampicin (rifampin), phenytoin, carbamazepine,
                  rifabutin, phenobarbital

               -  warfarin, dicoumarin, digoxin

               -  systemic glucocorticoids

         12. Patients who have taken anti-obesity drugs or had a surgery related to obesity within
             12 weeks before Visit 1 (screening)

         13. Patients who have received insulin and GLP-1 analogue treatment within 8 weeks prior
             to Visit 1 (screening)

         14. Patients who have received a treatment due to malignant tumor within 5years before
             Visit 1 (screening) However, patients whose basal cell or squamous cell skin cancer or
             in situ cervical cancer has been treated can be enrolled.

         15. Patients with a history of myocardial infarction, unstable angina and coronary artery
             bypass surgery within 6 months prior to Visit 1 (screening)

         16. Patients with a history of alcohol or drug addiction within 1 year prior to Visit 1
             (screening)

         17. Patients who have a medical history of hypersensitivity to the same class as
             Gemigliptin or dipeptidyl peptidase 4 (DPP 4) inhibitor drugs

         18. Patients with a history of hypersensitivity to the drugs belonging to the same class
             as Glimepiride or sulfonylureas and sulfonamide

         19. Patients who have participated in another clinical trial within 3 months prior to
             Visit 1 (screening)

         20. Patients deemed unsuitable for this trial based on the judgment of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong Hee Jin</last_name>
    <phone>82-2-6924-3122</phone>
    <email>jonghee@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cha</last_name>
      <email>songppm@cmcnu.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

